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Corticosteroids effectively suppress granulomatous inflam-
mation in sarcoidosis. However, the role of corticosteroids
remains unsettled nearly sixty years after the first report of
their benefits.1 As in other contentious areas of medicine,
we prioritize evidence from controlled clinical trials to
guide decision-making. Despite the paucity of randomized,
double-blind controlled evidence, the preponderance of
data from the available trials is congruent: treatment of
acute sarcoidosis is “on-balance” beneficial. To provide
focus, I will limit my comments to recent-onset pulmonary
sarcoidosis, defined as less than five years since diagnosis.2
What are the benefits of treatment?
Targeted use of corticosteroids (CS) has been widely rec-
ommended in acute pulmonary sarcoidosis for patients with
severe or progressive disease.1e3 This recommendation is
based on decades of accumulated clinical experience, as
well as several controlled trials that demonstrated clinically-
important improvements of symptoms, chest radiographs
and physiologic parameters.4e7 During long-term treatment,* Associate Editor, Dr. Marc A. Judson refereed this debate. He
edited this debate for purposes of internal consistency; these edits
did not significantly affect the debate’s content.
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doi:10.1016/j.rmed.2010.07.001observational data confirmed that low-dose CS preserve lung
function in both acute and chronic disease.8 Since fibrosis
is thought to result from uncontrolled granulomatous
inflammation, suppression of granulomas should prevent its
development or progression. It is patently obvious that
a placebo-controlled trial in patients with active disease and
a fibrogenic phenotype would be unethical. On the other
hand, most of the available data also suggest that treatment
of patientswith a high chance of good outcomes (e.g., Stage I
CXR) does not confer substantial benefits.5,9,10
In clinical practice the picture is not always so black-
and-white. What should be done with patients who have
disabling impairment of their quality of life from systemic
symptoms, but without any at-risk organ? What about
patients with modest physiologic impairment and mild
to moderate symptoms? Some authors have suggested
that these patients may also benefit from a short course of
CS, under the rubric of a patient-led discussion about the
pros and cons of therapy.11,12 If we took the viewpoint that
treatment of non life-threatening disease somehow harms
the patient, we might not favor any therapy for them.
Should we be asking patients to delay relief of symptoms to
allow more time for a spontaneous remission, a “natural
deus ex machina”, to relieve us of making a decision?
Effect of treatment on the natural history
Controlled trials provide some information about whether
more aggressive treatment influences the course of the
disease. The first randomized, double-blind placebo-.
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by Israel et al. in 90 African-Americans with recent-onset
sarcoidosis and no immediate treatment indications.5 After
a mean follow-up period of 5.3 years, the rate of serious
relapse or progression was lower in patients randomized to
three months of prednisone compared with placebo (24% vs.
38%). The final chest radiograph findings however, were not
statistically different. When subsequent controlled studies
of long-term outcomes failed to show a consistent durable
benefit for corticosteroids, a general bias arose that corti-
costeroids do not influence the natural course of the
disease.4,7,9,13,14 It is worth noting that none of these trials
suggested a substantial long-term harm. Additionally, all the
older studies suffer from multiple severe methodological
flaws, including lack of placebo control, high rates of unac-
counted drop-outs, fuzzy end-points, high proportions of
patients with expected benign courses, and substantial
under-powering. Indeed, data from similar idiopathic
immune-mediated diseases, such as Crohn’s disease and
rheumatoid arthritis,15,16 suggest that wemay have been too
un-aggressivewith early therapy, rather than too aggressive,
if the goal is to influence the natural history.17
Two trials with more rigorous designs both suggest
possible long-term benefits of early treatment. Pietinalho et
al. randomized 189 newly-diagnosed Finnish patients to
3months of prednisolone followed by inhaled budesonide for
15 months or to matching placebo.10,18 Over the subsequent
3½year follow-up, treated patientswith baseline Stages 2e3
CXR exhibited improvements in FVC and DLCO (net mean
differences of þ0.33L and þ0.76 mm/kpa, respectively
comparedwith placebo).18 In patientswithmore severe PFTs
at baseline, the differences were greater and were apparent
at the end of the three month systemic treatment period.
During the follow-up period, 16/79 patients in the placebo
group experienced a relapse, vs. 2/70 of the CS patients
(p< 0.001). The results of this study are confounded by the
sequential treatment with ICS, however, the bulk of thera-
peutic trials for ICS have been negative.19
A British Thoracic Society (BTS) trial focused on acute
sarcoidosis with persistent infiltrates and no immediate
treatment indications.20 Of 183 patients with Stages 2e3
chest radiographs, 58 patients neither deteriorated nor
improved during an initial six month observation period
after diagnosis. The utility of the six-month time point has
been confirmed in the ACCESS cohort, where the require-
ment for CS at six months was the strongest predictor of
clinically bothersome disease at two years.21 These 58
subjects were alternately assigned to treatment with
prednisolone (30 mg daily tapered to a goal maintenance
dose of 10 mg daily, n Z 27) for 18 months or treatment
only if there was definite deterioration (nZ 31). The dose
was adjusted to maintain the maximum radiographic
improvement without intolerable side-effects. The number
of patients requiring CS at the end of the trial was 5/27 in
the treated group vs. 4/31 in the observation group.
Dyspnea was less in the treatment group at 5 years, despite
the absence of baseline differences in dyspnea. Fibrosis
score increased in the observation group but decreased in
the treatment group. FVC and TLco both improved only in
the treatment group. These two larger well-designed trials
both point in one direction and accord with the early work
by Israel et al.: long-term course is favorably affected byearly use of CS but proof requires well-designed trials,
rigorous follow-up, and adequate numbers of participants.Are corticosteroids harmful?
Corticosteroids can cause toxicity and hypothetically
may adversely affect the prospects for spontaneous reso-
lution. Since the major toxicities of CS are dose-depen-
dent, it follows that treatment strategies that minimize
the cumulative dose will lead to a more favorable risk-
benefit ratio. In a series of 181 patients followed longi-
tudinally at Johns Hopkins, 91% were successfully main-
tained with 15 mg/d and 65% 10 mg/d of prednisone.22
Other authors also have suggested that pulmonary
sarcoidosis should rarely require average prednisone doses
>20 mg/d, and that tapering can start within one
month.7,23,24 These observations suggest that many of the
purported toxicities of corticosteroids may be a function
of overly aggressive dosing regimens. Despite this fact, the
data from most of the controlled trials do not support
a major toxicity risk. When side-effects develop they are
typically minor and reversible.10,20,25 For example, the
median excess weight gain due to corticosteroids in
controlled trials ranges from 3.6 to 5 kg,20,26 and there
were no persistent differences between treated and
untreated groups at 5 years in the BTS study.20 I agree with
DeRemee that the toxicities of properly managed corti-
costeroid regimens are substantially over-stated.17 In
addition, the advent of a range of effective steroid-
sparing agents allows successful mitigation of many of the
purported therapy-limiting toxicities.
Do corticosteroids prevent resolution of sarcoidosis? In
a single-center retrospective series, relapse rates were 74%
if corticosteroids were used to induce “remission,” whereas
patients who had experienced spontaneous remissions
relapsed only 8% of the time.27 Swedish Lo¨fgren’s patients
with HLA DRB1*03 relapsed more frequently if they were
treated with CS.28 However, the implication that CS
prevent remissions is not really borne out by the data
available from the controlled trials. If treatment did
prevent resolution of sarcoidosis, one would expect that
subjects in the treatment arm of the CS trials would
demonstrate worse outcomes, but they do not.
Conclusion
Having sarcoidosis approximately doubles the mortality
rate29; sarcoidosis mortality and morbidity in the U.S. and
Europe are mainly related to progressive lung disease. For
example, the effects of pulmonary sarcoidosis on quality of
life are similar to those reported in survivors of ARDS, AIDS,
end stage renal disease and moderate to severe COPD.30e35
Although there are trials that show no long-term benefits of
early CS treatment, the most rigorous studies suggest lower
rates of relapse, better lung function, fewer symptoms and
less fibrosis. Importantly, there is no strong signal in the
available studies to suggest a worse long-term outcome in
the treated patients. While not advocating that every
patient with recent-onset sarcoidosis should be treated, is
the use of CS, on balance, beneficial? Some clinical
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controversy is the existence of a large gray area. It is our
opinion that the risks to the patient of progressive pulmo-
nary disease are far weightier than the risks of steroid
toxicity. In conclusion, the best data available now all
suggest that the judicious and titrated use of CS is more
likely to be beneficial than to be harmful. As the evidence
stands today, the burden of proof is now on the question:
“why wouldn’t you treat a patient with acute sarcoidosis”?References
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